FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198469802> ?p ?o ?g. }

• W3198469802 endingPage "e640" @default.
• W3198469802 startingPage "e631" @default.
• W3198469802 abstract "Abstract: Cardiovascular (CV) disease remains the leading cause of death in the United States. In addition to lifestyle modifications, current guidelines primarily focus on lowering low-density lipoprotein cholesterol (LDL-C) to reduce atherosclerotic CV disease risk. However, despite aggressive management, a degree of residual risk remains, suggesting that focusing on lowering LDL-C alone may be inadequate and that other lipid parameters may need to be targeted. In patients who remain at high risk despite current pharmacologic options either because of inadequate response, elevated levels of other lipoproteins, or those who have genetic variants predisposing them to atherosclerotic CV disease, additional treatment strategies continue to be sought. One such group is the homozygous familial hypercholesterolemia population, especially those patients carrying the null low-density lipoprotein receptor mutation as they often fail to derive the same benefit from traditional LDL-C lower strategies such as statins and proprotein convertase subtilisin/kexin type 9 inhibitors that work by upregulating the LDL receptor. Emerging data also suggest that patients with increased levels of triglyceride-rich lipoproteins are also at increased risk as elevated levels are proposed to have a role in various pathways promoting atherogenesis. Angiopoietin-life protein 3 (ANGLTPL3) has recently become a target of interest because of the discovery that inhibiting its action leads to reductions in lipid parameters. Although the mechanism of action of ANGLTPL3 inhibitors is independent of the LDL receptor, their ability to significantly lower triglycerides and LDL-C make them an attractive option particularly in patients with homozygous familial hypercholesterolemia and hypertriglyceridemia. The efficacy and safety of 2 ANGLTPL3 inhibitor agents have been evaluated in clinical trials. In this review, the lipid lowering, metabolic effects, and safety are reported. Ongoing trials assessing CV outcomes as well as long-term safety data are still needed to provide a more definitive role for these agents in the overall management in these populations." @default.
• W3198469802 created "2021-09-13" @default.
• W3198469802 creator A5040890060 @default.
• W3198469802 date "2021-11-01" @default.
• W3198469802 modified "2023-10-16" @default.
• W3198469802 title "Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies" @default.
• W3198469802 cites W1520609538 @default.
• W3198469802 cites W1586368641 @default.
• W3198469802 cites W1944135887 @default.
• W3198469802 cites W1957970362 @default.
• W3198469802 cites W1976428272 @default.
• W3198469802 cites W2001609219 @default.
• W3198469802 cites W2014004431 @default.
• W3198469802 cites W2020915011 @default.
• W3198469802 cites W2069898248 @default.
• W3198469802 cites W2077907566 @default.
• W3198469802 cites W2079699385 @default.
• W3198469802 cites W2088460845 @default.
• W3198469802 cites W2095786854 @default.
• W3198469802 cites W2100800328 @default.
• W3198469802 cites W2106937178 @default.
• W3198469802 cites W2109095803 @default.
• W3198469802 cites W2116015900 @default.
• W3198469802 cites W2118676558 @default.
• W3198469802 cites W2127427274 @default.
• W3198469802 cites W2132196134 @default.
• W3198469802 cites W2139168645 @default.
• W3198469802 cites W2159449551 @default.
• W3198469802 cites W2160256386 @default.
• W3198469802 cites W2164167307 @default.
• W3198469802 cites W2168876694 @default.
• W3198469802 cites W2170009139 @default.
• W3198469802 cites W2234444148 @default.
• W3198469802 cites W2275234007 @default.
• W3198469802 cites W2286999219 @default.
• W3198469802 cites W2323589075 @default.
• W3198469802 cites W2342925409 @default.
• W3198469802 cites W2345841042 @default.
• W3198469802 cites W2531285001 @default.
• W3198469802 cites W2589215191 @default.
• W3198469802 cites W2604768034 @default.
• W3198469802 cites W2606804985 @default.
• W3198469802 cites W2617605538 @default.
• W3198469802 cites W2618984243 @default.
• W3198469802 cites W2730976293 @default.
• W3198469802 cites W2747795314 @default.
• W3198469802 cites W2763968521 @default.
• W3198469802 cites W2771532173 @default.
• W3198469802 cites W2792834220 @default.
• W3198469802 cites W2810548862 @default.
• W3198469802 cites W2899669642 @default.
• W3198469802 cites W2899997727 @default.
• W3198469802 cites W2918535553 @default.
• W3198469802 cites W2955013370 @default.
• W3198469802 cites W3004830249 @default.
• W3198469802 cites W3036498507 @default.
• W3198469802 cites W3039823791 @default.
• W3198469802 cites W3041635484 @default.
• W3198469802 cites W3061843793 @default.
• W3198469802 cites W3129818723 @default.
• W3198469802 cites W4241035150 @default.
• W3198469802 cites W95816509 @default.
• W3198469802 doi "https://doi.org/10.1097/fjc.0000000000001132" @default.
• W3198469802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34738550" @default.
• W3198469802 hasPublicationYear "2021" @default.
• W3198469802 type Work @default.
• W3198469802 sameAs 3198469802 @default.
• W3198469802 citedByCount "0" @default.
• W3198469802 crossrefType "journal-article" @default.
• W3198469802 hasAuthorship W3198469802A5040890060 @default.
• W3198469802 hasConcept C126322002 @default.
• W3198469802 hasConcept C134018914 @default.
• W3198469802 hasConcept C152163801 @default.
• W3198469802 hasConcept C2776919658 @default.
• W3198469802 hasConcept C2778163477 @default.
• W3198469802 hasConcept C2778849439 @default.
• W3198469802 hasConcept C2778913445 @default.
• W3198469802 hasConcept C2779134260 @default.
• W3198469802 hasConcept C2780072125 @default.
• W3198469802 hasConcept C2780948078 @default.
• W3198469802 hasConcept C2908647359 @default.
• W3198469802 hasConcept C43554185 @default.
• W3198469802 hasConcept C60644358 @default.
• W3198469802 hasConcept C71924100 @default.
• W3198469802 hasConcept C86803240 @default.
• W3198469802 hasConcept C99454951 @default.
• W3198469802 hasConceptScore W3198469802C126322002 @default.
• W3198469802 hasConceptScore W3198469802C134018914 @default.
• W3198469802 hasConceptScore W3198469802C152163801 @default.
• W3198469802 hasConceptScore W3198469802C2776919658 @default.
• W3198469802 hasConceptScore W3198469802C2778163477 @default.
• W3198469802 hasConceptScore W3198469802C2778849439 @default.
• W3198469802 hasConceptScore W3198469802C2778913445 @default.
• W3198469802 hasConceptScore W3198469802C2779134260 @default.
• W3198469802 hasConceptScore W3198469802C2780072125 @default.
• W3198469802 hasConceptScore W3198469802C2780948078 @default.
• W3198469802 hasConceptScore W3198469802C2908647359 @default.
• W3198469802 hasConceptScore W3198469802C43554185 @default.

• next